Skip to main content
Erschienen in: Critical Care 2/2011

01.04.2011 | Commentary

The role of receptor for advanced glycation endproducts (RAGE) in infection

verfasst von: Marieke AD van Zoelen, Ahmed Achouiti, Tom van der Poll

Erschienen in: Critical Care | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Excerpt

During evolution, multicellular organisms have developed an impressive arsenal of defense and repair mechanisms to counteract threats such as infection and trauma. Such an inflammatory response begins with the detection of the potential life-threatening event by recognizing so-called danger signals. These signal molecules have been classically divided into: i) Exogenous, pathogen-associated molecular patterns (PAMPs) [1], which are conserved motifs on pathogens that are not found in higher eukaryocytes; and ii) endogenous innate danger molecules, also named damage-associated molecular patterns (DAMPs) or alarmins, which are structurally diverse proteins rapidly released by the host itself during infection or (sterile) tissue damage [2]. …
Literatur
1.
Zurück zum Zitat Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002, 20: 197-216. 10.1146/annurev.immunol.20.083001.084359CrossRefPubMed Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002, 20: 197-216. 10.1146/annurev.immunol.20.083001.084359CrossRefPubMed
2.
Zurück zum Zitat Bianchi ME: DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 2007, 81: 1-5. 10.1189/jlb.0306164CrossRefPubMed Bianchi ME: DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 2007, 81: 1-5. 10.1189/jlb.0306164CrossRefPubMed
3.
Zurück zum Zitat Harris HE, Raucci A: Alarmin(g) News about danger: Workshop on innate danger signals and HMGB1. EMBO Rep 2006, 7: 774-778.PubMedCentralPubMed Harris HE, Raucci A: Alarmin(g) News about danger: Workshop on innate danger signals and HMGB1. EMBO Rep 2006, 7: 774-778.PubMedCentralPubMed
4.
Zurück zum Zitat Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418: 191-195. 10.1038/nature00858CrossRefPubMed Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418: 191-195. 10.1038/nature00858CrossRefPubMed
5.
Zurück zum Zitat Liu Y, Chen GY, Zheng P: CD24-Siglec G/10 discriminates danger-from pathogen-associated molecular patterns. Trends Immunol 2009, 30: 557-561. 10.1016/j.it.2009.09.006PubMedCentralCrossRefPubMed Liu Y, Chen GY, Zheng P: CD24-Siglec G/10 discriminates danger-from pathogen-associated molecular patterns. Trends Immunol 2009, 30: 557-561. 10.1016/j.it.2009.09.006PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Liu R, Mori S, Wake H, et al.: Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin's effect on binding. Acta Med Okayama 2009, 63: 203-211.PubMed Liu R, Mori S, Wake H, et al.: Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin's effect on binding. Acta Med Okayama 2009, 63: 203-211.PubMed
7.
Zurück zum Zitat Bierhaus A, Stern DM, Nawroth PP: RAGE in inflammation: a new therapeutic Target? Curr Opin Investig Drugs 2006, 7: 985-991.PubMed Bierhaus A, Stern DM, Nawroth PP: RAGE in inflammation: a new therapeutic Target? Curr Opin Investig Drugs 2006, 7: 985-991.PubMed
8.
Zurück zum Zitat Chavakis T, Bierhaus A, Al Fakhri N, et al.: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003, 198: 1507-1515. 10.1084/jem.20030800PubMedCentralCrossRefPubMed Chavakis T, Bierhaus A, Al Fakhri N, et al.: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003, 198: 1507-1515. 10.1084/jem.20030800PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Liliensiek B, Weigand MA, Bierhaus A, et al.: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004, 113: 1641-1650.PubMedCentralCrossRefPubMed Liliensiek B, Weigand MA, Bierhaus A, et al.: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004, 113: 1641-1650.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Goova MT, Li J, Kislinger T, et al.: Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001, 159: 513-525. 10.1016/S0002-9440(10)61723-3PubMedCentralCrossRefPubMed Goova MT, Li J, Kislinger T, et al.: Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001, 159: 513-525. 10.1016/S0002-9440(10)61723-3PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Cataldegirmen G, Zeng S, Feirt N, et al.: RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 2005, 201: 473-484. 10.1084/jem.20040934PubMedCentralCrossRefPubMed Cataldegirmen G, Zeng S, Feirt N, et al.: RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 2005, 201: 473-484. 10.1084/jem.20040934PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Park L, Raman KG, Lee KJ, et al.: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998, 4: 1025-1031. 10.1038/2012CrossRefPubMed Park L, Raman KG, Lee KJ, et al.: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998, 4: 1025-1031. 10.1038/2012CrossRefPubMed
13.
Zurück zum Zitat Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001, 108: 949-955.PubMedCentralCrossRefPubMed Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001, 108: 949-955.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5: 331-342. 10.1038/nri1594CrossRefPubMed Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5: 331-342. 10.1038/nri1594CrossRefPubMed
15.
Zurück zum Zitat Ueno H, Matsuda T, Hashimoto S, et al.: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004, 170: 1310-1316. 10.1164/rccm.200402-188OCCrossRefPubMed Ueno H, Matsuda T, Hashimoto S, et al.: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004, 170: 1310-1316. 10.1164/rccm.200402-188OCCrossRefPubMed
16.
Zurück zum Zitat Wang H, Bloom O, Zhang M, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285: 248-251. 10.1126/science.285.5425.248CrossRefPubMed Wang H, Bloom O, Zhang M, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285: 248-251. 10.1126/science.285.5425.248CrossRefPubMed
17.
Zurück zum Zitat van Zoelen MA, Laterre PF, van Veen SQ, et al.: Systemic and local high mobility group box 1 concentrations during severe infection. Crit Care Med 2007, 35: 2799-2804. 10.1097/01.CCM.0000287588.69000.97CrossRefPubMed van Zoelen MA, Laterre PF, van Veen SQ, et al.: Systemic and local high mobility group box 1 concentrations during severe infection. Crit Care Med 2007, 35: 2799-2804. 10.1097/01.CCM.0000287588.69000.97CrossRefPubMed
18.
Zurück zum Zitat Yang H, Ochani M, Li J, et al.: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004, 101: 296-301. 10.1073/pnas.2434651100PubMedCentralCrossRefPubMed Yang H, Ochani M, Li J, et al.: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004, 101: 296-301. 10.1073/pnas.2434651100PubMedCentralCrossRefPubMed
19.
20.
Zurück zum Zitat Suda K, Kitagawa Y, Ozawa S, et al.: Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 2006, 30: 1755-1762. 10.1007/s00268-005-0369-2CrossRefPubMed Suda K, Kitagawa Y, Ozawa S, et al.: Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 2006, 30: 1755-1762. 10.1007/s00268-005-0369-2CrossRefPubMed
21.
Zurück zum Zitat Wang H, Liao H, Ochani M, et al.: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004, 10: 1216-1221. 10.1038/nm1124CrossRefPubMed Wang H, Liao H, Ochani M, et al.: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004, 10: 1216-1221. 10.1038/nm1124CrossRefPubMed
22.
Zurück zum Zitat Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006, 6: 813-822. 10.1038/nri1943CrossRefPubMed Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006, 6: 813-822. 10.1038/nri1943CrossRefPubMed
23.
Zurück zum Zitat Hotchkiss RS, Chang KC, Swanson PE, et al.: Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000, 1: 496-501. 10.1038/82741CrossRefPubMed Hotchkiss RS, Chang KC, Swanson PE, et al.: Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000, 1: 496-501. 10.1038/82741CrossRefPubMed
24.
Zurück zum Zitat Tian J, Avalos AM, Mao SY, et al.: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8: 487-496. 10.1038/ni1457CrossRefPubMed Tian J, Avalos AM, Mao SY, et al.: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8: 487-496. 10.1038/ni1457CrossRefPubMed
25.
Zurück zum Zitat Yang H, Hreggvidsdottir HS, Palmblad K, et al.: A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010, 107: 11942-11947. 10.1073/pnas.1003893107PubMedCentralCrossRefPubMed Yang H, Hreggvidsdottir HS, Palmblad K, et al.: A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010, 107: 11942-11947. 10.1073/pnas.1003893107PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Wittkowski H, Sturrock A, van Zoelen MA, et al.: Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 2007, 35: 1369-1375. 10.1097/01.CCM.0000262386.32287.29CrossRefPubMed Wittkowski H, Sturrock A, van Zoelen MA, et al.: Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 2007, 35: 1369-1375. 10.1097/01.CCM.0000262386.32287.29CrossRefPubMed
27.
Zurück zum Zitat Orlova VV, Choi EY, Xie C, et al.: A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007, 26: 1129-1139. 10.1038/sj.emboj.7601552PubMedCentralCrossRefPubMed Orlova VV, Choi EY, Xie C, et al.: A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007, 26: 1129-1139. 10.1038/sj.emboj.7601552PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Frommhold D, Kamphues A, Hepper I, et al.: RAGE and ICAM-1 Cooperate in mediating leukocyte recruitment during acute inflammation in vivo. Blood 2010, 116: 841-849. 10.1182/blood-2009-09-244293CrossRefPubMed Frommhold D, Kamphues A, Hepper I, et al.: RAGE and ICAM-1 Cooperate in mediating leukocyte recruitment during acute inflammation in vivo. Blood 2010, 116: 841-849. 10.1182/blood-2009-09-244293CrossRefPubMed
29.
Zurück zum Zitat Uchida T, Shirasawa M, Ware LB, et al.: Receptor for advanced glycation end-products is a marker of type i cell injury in acute lung injury. Am J Respir Crit Care Med 2006, 173: 1008-1015. 10.1164/rccm.200509-1477OCPubMedCentralCrossRefPubMed Uchida T, Shirasawa M, Ware LB, et al.: Receptor for advanced glycation end-products is a marker of type i cell injury in acute lung injury. Am J Respir Crit Care Med 2006, 173: 1008-1015. 10.1164/rccm.200509-1477OCPubMedCentralCrossRefPubMed
30.
Zurück zum Zitat Cheng C, Tsuneyama K, Kominami R, et al.: Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 2005, 18: 1385-1396. 10.1038/modpathol.3800450CrossRefPubMed Cheng C, Tsuneyama K, Kominami R, et al.: Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 2005, 18: 1385-1396. 10.1038/modpathol.3800450CrossRefPubMed
31.
Zurück zum Zitat Englert JM, Hanford LE, Kaminski N, et al.: A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 2008, 172: 583-591. 10.2353/ajpath.2008.070569PubMedCentralCrossRefPubMed Englert JM, Hanford LE, Kaminski N, et al.: A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 2008, 172: 583-591. 10.2353/ajpath.2008.070569PubMedCentralCrossRefPubMed
32.
Zurück zum Zitat Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M: The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol 2006, 19: 1437-1445.PubMed Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M: The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol 2006, 19: 1437-1445.PubMed
33.
Zurück zum Zitat Buckley ST, Ehrhardt C: The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol. 2010, 2010: 917108. Buckley ST, Ehrhardt C: The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol. 2010, 2010: 917108.
34.
Zurück zum Zitat Queisser MA, Kouri FM, Konigshoff M, et al.: Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types. Am J Respir Cell Mol Biol 2008, 39: 337-345. 10.1165/rcmb.2007-0244OCCrossRefPubMed Queisser MA, Kouri FM, Konigshoff M, et al.: Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types. Am J Respir Cell Mol Biol 2008, 39: 337-345. 10.1165/rcmb.2007-0244OCCrossRefPubMed
35.
Zurück zum Zitat Demling N, Ehrhardt C, Kasper M, Laue M, Knels L, Rieber EP: Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res 2006, 323: 475-488. 10.1007/s00441-005-0069-0CrossRefPubMed Demling N, Ehrhardt C, Kasper M, Laue M, Knels L, Rieber EP: Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res 2006, 323: 475-488. 10.1007/s00441-005-0069-0CrossRefPubMed
36.
Zurück zum Zitat Fehrenbach H, Kasper M, Tschernig T, Shearman MS, Schuh D, Muller M: Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell Mol Biol 1998, 44: 1147-1157.PubMed Fehrenbach H, Kasper M, Tschernig T, Shearman MS, Schuh D, Muller M: Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell Mol Biol 1998, 44: 1147-1157.PubMed
37.
Zurück zum Zitat He M, Kubo H, Ishizawa K, et al.: The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007, 293: L1427-L1436. 10.1152/ajplung.00075.2007CrossRefPubMed He M, Kubo H, Ishizawa K, et al.: The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007, 293: L1427-L1436. 10.1152/ajplung.00075.2007CrossRefPubMed
38.
Zurück zum Zitat Reynolds PR, Schmitt RE, Kasteler SD, et al.: Receptors for advanced glycation end-products targeting protect against hyperoxia-induced lung injury in mice. Am J Respir Cell Mol Biol 2010, 42: 545-551. 10.1165/rcmb.2008-0265OCCrossRefPubMed Reynolds PR, Schmitt RE, Kasteler SD, et al.: Receptors for advanced glycation end-products targeting protect against hyperoxia-induced lung injury in mice. Am J Respir Cell Mol Biol 2010, 42: 545-551. 10.1165/rcmb.2008-0265OCCrossRefPubMed
39.
Zurück zum Zitat van Zoelen MA, Schouten M, de Vos AF, et al.: The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 2009, 182: 4349-4356. 10.4049/jimmunol.0801199CrossRefPubMed van Zoelen MA, Schouten M, de Vos AF, et al.: The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 2009, 182: 4349-4356. 10.4049/jimmunol.0801199CrossRefPubMed
40.
Zurück zum Zitat van Zoelen MA, van der Sluijs KF, Achouiti A, et al.: Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 2009, 391: 265-273. 10.1016/j.virol.2009.05.032PubMedCentralCrossRefPubMed van Zoelen MA, van der Sluijs KF, Achouiti A, et al.: Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 2009, 391: 265-273. 10.1016/j.virol.2009.05.032PubMedCentralCrossRefPubMed
41.
Zurück zum Zitat Lutterloh EC, Opal SM, Pittman DD, et al.: Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007, 11: R122. 10.1186/cc6184PubMedCentralCrossRefPubMed Lutterloh EC, Opal SM, Pittman DD, et al.: Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007, 11: R122. 10.1186/cc6184PubMedCentralCrossRefPubMed
42.
Zurück zum Zitat van Zoelen MA, Schmidt AM, Florquin S, et al.: Receptor for advanced glycation end products facilitates host defense during Escherichia coli-induced abdominal sepsis in mice. J Infect Dis 2009, 200: 765-773. 10.1086/604730CrossRefPubMed van Zoelen MA, Schmidt AM, Florquin S, et al.: Receptor for advanced glycation end products facilitates host defense during Escherichia coli-induced abdominal sepsis in mice. J Infect Dis 2009, 200: 765-773. 10.1086/604730CrossRefPubMed
43.
Zurück zum Zitat van Zoelen MA, Achouiti A, Schmidt AM, et al.: Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during escherichia coli peritonitis. Crit Care Med 2010, 38: 1414-1422. 10.1097/CCM.0b013e3181de18bcPubMedCentralCrossRefPubMed van Zoelen MA, Achouiti A, Schmidt AM, et al.: Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during escherichia coli peritonitis. Crit Care Med 2010, 38: 1414-1422. 10.1097/CCM.0b013e3181de18bcPubMedCentralCrossRefPubMed
44.
Zurück zum Zitat van Zoelen MA, Yang H, Florquin S, et al.: Role of Toll-Like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009, 31: 280-284. 10.1097/SHK.0b013e318186262dPubMedCentralCrossRefPubMed van Zoelen MA, Yang H, Florquin S, et al.: Role of Toll-Like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009, 31: 280-284. 10.1097/SHK.0b013e318186262dPubMedCentralCrossRefPubMed
45.
Zurück zum Zitat Park JS, Svetkauskaite D, He Q, et al.: Involvement of Toll-Like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279: 7370-7377. 10.1074/jbc.M306793200CrossRefPubMed Park JS, Svetkauskaite D, He Q, et al.: Involvement of Toll-Like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279: 7370-7377. 10.1074/jbc.M306793200CrossRefPubMed
46.
Zurück zum Zitat Payen D, Lukaszewicz AC, Belikova I, et al.: Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med 2008, 34: 1371-1376. 10.1007/s00134-008-1048-1CrossRefPubMed Payen D, Lukaszewicz AC, Belikova I, et al.: Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med 2008, 34: 1371-1376. 10.1007/s00134-008-1048-1CrossRefPubMed
47.
Zurück zum Zitat Foell D, Wittkowski H, Vogl T, Roth J: S100 Proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81: 28-37. 10.1189/jlb.0306170CrossRefPubMed Foell D, Wittkowski H, Vogl T, Roth J: S100 Proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81: 28-37. 10.1189/jlb.0306170CrossRefPubMed
48.
Zurück zum Zitat Cole AM, Kim YH, Tahk S, et al.: Calcitermin, a novel antimicrobial peptide isolated from human airway secretions. FEBS Lett 2001, 504: 5-10. 10.1016/S0014-5793(01)02731-4CrossRefPubMed Cole AM, Kim YH, Tahk S, et al.: Calcitermin, a novel antimicrobial peptide isolated from human airway secretions. FEBS Lett 2001, 504: 5-10. 10.1016/S0014-5793(01)02731-4CrossRefPubMed
49.
Zurück zum Zitat Bopp C, Hofer S, Weitz J, et al.: SRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008, 147: 79-83. 10.1016/j.jss.2007.07.014CrossRefPubMed Bopp C, Hofer S, Weitz J, et al.: SRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008, 147: 79-83. 10.1016/j.jss.2007.07.014CrossRefPubMed
50.
Zurück zum Zitat Hudson BI, Harja E, Moser B, Schmidt AM: Soluble levels of receptor for advanced glycation endproducts (SRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol 2005, 25: 879-882. 10.1161/01.ATV.0000164804.05324.8bCrossRefPubMed Hudson BI, Harja E, Moser B, Schmidt AM: Soluble levels of receptor for advanced glycation endproducts (SRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol 2005, 25: 879-882. 10.1161/01.ATV.0000164804.05324.8bCrossRefPubMed
Metadaten
Titel
The role of receptor for advanced glycation endproducts (RAGE) in infection
verfasst von
Marieke AD van Zoelen
Ahmed Achouiti
Tom van der Poll
Publikationsdatum
01.04.2011
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 2/2011
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc9990

Weitere Artikel der Ausgabe 2/2011

Critical Care 2/2011 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.